{"filing":{"accession_number":"0001731122-26-001173","cik":"0001553788","ticker":"SBEVW","company_name":"Endovia Health Sciences, Inc.","form":"8-K","filing_date":"2026-08-31","report_date":"2026-08-31","primary_document":"e7903_8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226001173/e7903_8-k.htm"},"events":[{"id":30608,"run_id":28059,"accession_number":"0001731122-26-001173","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"The press release discloses Endovia's response to federal marijuana rescheduling developments (DEA support for Schedule III transfer), advancement of its CannEpil® FDA submission strategy, and plans to expand its cannabinoid-based pipeline through licensing and acquisition opportunities. While the filing touches on regulatory developments and product advancement, the core disclosure is operational and strategic—the company's positioning within an evolving regulatory environment and its pipeline expansion plans. This does not fit neatly into specific categories like `debt_issuance`, `ma_activity` (no deal announced), or `earnings_release`, making `operational_other` the most appropriate classification for a material strategic and business development disclosure.","company_name":"Endovia Health Sciences, Inc.","ticker":"SBEVW","filing_date":"2026-08-31","form":"8-K","submitted_at":null,"items":[{"id":33254,"accession_number":"0001731122-26-001173","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The press release discloses Endovia's response to federal marijuana rescheduling developments (DEA support for Schedule III transfer), advancement of its CannEpil® FDA submission strategy, and plans to expand its cannabinoid-based pipeline through licensing and acquisition opportunities. While the filing touches on regulatory developments and product advancement, the core disclosure is operational and strategic—the company's positioning within an evolving regulatory environment and its pipeline expansion plans. This does not fit neatly into specific categories like `debt_issuance`, `ma_activity` (no deal announced), or `earnings_release`, making `operational_other` the most appropriate classification for a material strategic and business development disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T20:14:01.146115+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33254,"accession_number":"0001731122-26-001173","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The press release discloses Endovia's response to federal marijuana rescheduling developments (DEA support for Schedule III transfer), advancement of its CannEpil® FDA submission strategy, and plans to expand its cannabinoid-based pipeline through licensing and acquisition opportunities. While the filing touches on regulatory developments and product advancement, the core disclosure is operational and strategic—the company's positioning within an evolving regulatory environment and its pipeline expansion plans. This does not fit neatly into specific categories like `debt_issuance`, `ma_activity` (no deal announced), or `earnings_release`, making `operational_other` the most appropriate classification for a material strategic and business development disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T20:14:01.146115+00:00","company_name":"Endovia Health Sciences, Inc.","ticker":"SBEVW","filing_date":"2026-08-31"}]}